[Treatment of inflammatory diseases of the urogenital tract with eusaprim].
D000368:Aged; D003556:Cystitis / Q000188:drug therapy; D003967:Diarrhea / Q000209:etiology; D004823:Epididymitis / Q000188:drug therapy; D004926:Escherichia coli / Q000187:drug effects; D005493:Folic Acid Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006967:Hypersensitivity / Q000209:etiology; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009325:Nausea / Q000209:etiology; D011511:Proteus / Q000187:drug effects; D011704:Pyelonephritis / Q000188:drug therapy; D011743:Pyrimidines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013420:Sulfamethoxazole / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014515:Ureteral Diseases / Q000517:prevention & control; D014552:Urinary Tract Infections / Q000188:drug therapy*; D014839:Vomiting / Q000209:etiology
D005493:Folic Acid Antagonists; D011743:Pyrimidines; D013420:Sulfamethoxazole
Behandlung entzündlicher Erkrankungen des Urogenitaltraktes mit Eusaprim.